Lumos Pharma, Inc. (LUMO) Misses Q1 EPS by 3c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q1 EPS of ($0.92), $0.03 worse than the analyst estimate of ($0.89).

Lumos Pharma ended the quarter on March 31, 2022 with cash and cash equivalents totaling $86.8 million compared to $94.8 million on December 31, 2021. The Company expects an average cash use of approximately $8.5 to $9.5 million per quarter through 2022. Cash on hand as of March 31, 2022 is expected to support operations through the primary outcome data readout from the OraGrowtH210 Trial anticipated in the second half of 2023 and the OraGrowtH212 Trial

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• Marchex (MCHX) Reports In-Line Q2 EPS